Less than two years after…
Less than two years after emerging, Arena BioWorks is shuttering, [...]
Less than two years after emerging, Arena BioWorks is shuttering, [...]
Pfizer has axed 11 programs including two pipeline assets from [...]
Questex has acquired The Conference Forum and Versalinx Global Events, [...]
Tempero Bio has hit the brakes on a phase 2-stage [...]
FDA is said to be making a U-turn on uniQure’s [...]
Roche may have been exploring ways to shuttle drugs to [...]
Welcome to the Fierce Biotech Graveyard, our annual ritual remembering [...]
Nanobiotix is continuing to find fresh ways to eke money [...]
4DMT has sold the Asia-Pacific rights to its eye gene [...]
Gilead has chosen a partner for lenacapavir in the race [...]